

COPY

PATENT
Attorney Docket No. AGP-002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Rader

Application No.: 10/591,923

Confirmation No.:5393

Filed: June 21, 2007

Art Unit: 1614

For: Methods for Treating Disorders or Diseases
Associated with Hyperlipidemia

Examiner: K. Weddington

DECLARATION OF WILLIAM SASIELA, PH.D., UNDER 37 CFR 1.132

I, William Sasiela, hereby declare as follows:

1. I am Executive Vice President and Chief Medical Officer at Aegerion Pharmaceuticals, Inc, the licensee of the above referenced Patent Application.
2. I have extensive experience in lipid metabolism and therapies for atherosclerosis and related diseases, as evidenced by the copy of my curriculum vitae attached as Exhibit A.
3. I have read and understood the Application, including the currently-pending claims, and the cited prior art patents of Biller and Gregg.
4. I make this declaration in order to provide my scientific opinions and facts known to me which may be of assistance in the examination of the Application.
5. I understand that, prior to the claimed method for treating hyperlipidemia or hypercholesterolemia that includes stepwise increasing dose levels, the claimed MTP inhibitor had been the subject of human clinical trials for the treatment of hypercholesterolemia, where the MTP inhibitor was administered at a *constant* dose level of 25 mg/day or above. Because of adverse events that included clinically significant gastrointestinal steatorrhea and statistically significant hepatobiliary (elevation of liver function tests and fatty liver), the clinical trials and further development of the drug were discontinued, despite significant reduction in patient cholesterol.
6. To my knowledge, few medications for treatment of hyperlipidemia or hypercholesterolemia are administered to patients with stepwise increasing dose levels to minimize side effects. For example, manufacturers of statins, the world's largest category of lipid lowering drugs, have not employed, to my knowledge, step wise increasing doses (titration) in order to minimize side effects that would otherwise be observed at high doses. Ezetimibe (Zetia®), another type of lipid lowering drug, was developed and received FDA approval at a single

7. I believe that the claimed method for treating hyperlipidemia or hypercholesterolemia that includes stepwise increasing dose levels as recited in claim 1 would have not been obvious to a person skilled in the art at the time of the invention on the basis of any teaching of the Biller or Gregg patents and/or on the basis of general knowledge of those skilled in the art. I note that previous developers of this MTP inhibitor, who appear to have invested much thought and effort on the research and previous clinical trial did not arrive at a solution to the adverse events shown in patients at constant level dosing.
8. My colleagues and I have supervised Phase I, II, and III clinical trials, including Phase II randomized, double-blind human clinical trials, to assess the effectiveness and rate of adverse events of the instantly claimed methods of treating hyperlipidemia or hypercholesterolemia. I present below a summary of findings obtained using the claimed method.
9. Patients were administered low doses of the claimed MTP inhibitor (as pictorially represented in pending claim 1). Patients in study 1 were administered a *constant* level of 10 mg of the MTP inhibitor daily for 12 weeks. Patients in study 2, which included two arms, 2A, and 2B, were *first* administered 5 mg of the MTP inhibitor for 4 weeks, *then* administered 7.5 mg of the MTP inhibitor for 4 weeks, and *then* administered 10 mg of the MTP inhibitor for 4 more weeks. The results are depicted in Table A:

| Study (Total N) | Study | Study Duration | Rate of GI Discontinuations | Rate of GI adverse events | Rate of Diarrhea |
|-----------------|------------------------|----------------|-----------------------------|---------------------------|------------------|
| 1 (260) | 10 mg | 12 weeks | 9/35 | 30/35 (85.7%) | 23/35 (65.7%) |
| 2A (85) | 5→10 mg | 12 weeks | 2/28 | 18/28 (64.3%) | 11/28 (39.3%) |
| 2B (85) | 5→10 mg + 10 mg eze | 12 weeks | 1/28 | 12/28 (42.9%) | 10/28 (35.7%) |
| 3 (25)** | 5→60 mg | 78 weeks | 3/25 | 12/21 (57.1%) | 9/21 (42.9%) |

**Adverse event rates based on analysis of 21 treated patients

Table A

10. Patients in study 2A had a dramatic difference in the rate of patient discontinuation rate due to gastrointestinal (GI) effects, and in the rate of GI adverse events and diarrhea, as compared to study 1.
11. Patients in study 2B, like study 2A, were also first administered 5 mg of the MTP inhibitor for 4 weeks, *then* administered 7.5 mg of the MTP inhibitor for 4 weeks, and *then* administered 10 mg of the MTP inhibitor for 4 more weeks. These patients were additionally administered ezetimibe (10 mg daily, at a constant dosage level). Surprisingly, patients administered both ezetimibe and the claimed MTP inhibitor, starting at a 5 mg dose level for four weeks, also had significantly decreased GI adverse events and diarrhea, even compared to patients administered constant level of 10 mg of the MTP inhibitor *alone*.

12. Patients in study 3 suffer from homozygous familial hypercholesterolemia (hoFH), and were first administered 5 mg of the same MTP inhibitor used in study 1 and 2 for four weeks, then administered 10 mg of the MTP inhibitor for four weeks, then administered 20 mg of the MTP inhibitor for four weeks, then 40 mg of the MTP inhibitor for four weeks, then 60 mg of the MTP inhibitor, or to the highest tolerated dose.
13. Surprisingly, the patients in study 3, *initially administered 5 mg of MTP inhibitor*, and subsequently administered up to 60 mg of the MTP inhibitor, after escalation of dose levels to a mean dose level of 44 mg/day, show a lower rate of GI adverse events and diarrhea even as compared to the patients of study 1, who were administered a *constant level* of 10 mg of the MTP inhibitor.
14. I believe that the reduced incidence of GI adverse events and diarrhea in the patient groups 2 and 3, as indicated in Table A, is an unexpected result of the claimed method, especially as compared to administration of the same MTP inhibitor without escalating doses.
15. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the Application or any patent issued thereon.

Dated: April 8, 2010



William Sasieja, Ph.D.

WILLIAM J. SASIELA, PH.D.

124 Saxon Way
Skillman, NJ 08558
(609)651-3773
bsasiela@aol.com

EXECUTIVE PROFILE

Strong Phase II-Phase IV research background in the metabolic and cardiovascular therapeutic areas with particular interests and experience in lipids, atherosclerosis, diabetes and obesity. Research experience has covered many facets of development ranging phase II studies for small, orphan populations to multithousand, multiyear phase IIIb-IV CV event trials. Brings extensive experience in medical-marketing issues surrounding both US and Worldwide pharmaceutical markets in the metabolic and CV therapeutic areas. Strong track record of managing and creating cross-functional teams. Experience in evaluating strategic opportunities with individual compounds and within overall internal development programs. Noted for excellent speaking and communication abilities.

PROFESSIONAL EXPERIENCE

Aegerion Pharmaceuticals, Inc., Bridgewater, NJ 2005-Present
Executive Vice President & Chief Medical Officer

As the third employee to join the newly formed biotech company, had the responsibility for overall development strategy and programs, design of clinical trials and formation of internal clinical development team. Had overall responsibility for all facets of product development including clinical trials, manufacturing and regulatory functions.

- Development strategy for AEGR-733 and AEGR-427 for hyperlipidemia including phase 2 and phase 3 clinical trials as well as necessary preclinical and pharmacokinetic studies.
- Led team that successfully designed and executed 6 phase 2/3 clinical trials and 11 preclinical studies for AEGR-733.
- Creation of teams and hiring of personnel to support all developmental activities including clinical operations, regulatory affairs and manufacturing.
- Development and execution of all meetings relating to the Aegerion Scientific Advisory Board.
- Member of the Aegerion Executive team with participation and presentation at all Aegerion Board of Director meetings.
- Significant role in all private and public financing activities.
- Evaluation of all potential in-licensing candidates including compounds in the areas of type 2 diabetes (e.g. DDP-IV, long-acting insulin), dyslipidemia and cardiovascular disease.

Pfizer/Parke-Davis, New York, NY/Morris Plains, NJ

1996-2005

Senior Clinical Director/Worldwide Team Leader

2003-2005

Led Worldwide Medical Teams for Lipitor and the Atherosclerosis Development at Pfizer's NY headquarters. The latter group focused on developmental programs for in the area of lipids and atherosclerosis and included torcetrapib/atorvastatin program and the compounds that were acquired via the Esperion acquisition. During this period, worldwide revenues for Lipitor grew from \$7.9 B (2002) to \$12.2 B (2005). Also within this role, was member of cross-functional team that drove strategy for the entire CVME franchise within Pfizer from discovery to commercialization.

- Led the overall medical program and medical/marketing strategy for Lipitor worldwide including the clinical trial program, sNDAs and other regulatory responses, country/regional medical/marketing initiatives.
- Ensured alignment and appropriate roll-out of medical strategies between NYHQ, US and other key regions.
- Played integral role in the development of the extensive phase 3 program and proposed labeling for torcetrapib/atorvastatin
- Led efforts around lifecycle management for an established product (Lipitor) and an emerging product (torcetrapib/atorvastatin)
- Worked with Pfizer L&D team to identify and evaluate potential in-licensing candidates. Performed technical due diligence on compounds of interest.
- Contributed to overall PFE strategy in CVME through activity in Therapeutic Area Strategy Teams. In particular, led efforts around identification and prioritization of enabling strategies for all CVME development areas.
- Led a cross-functional team to develop strategies for validation of atherosclerosis imaging techniques and plasma biomarkers.
- Managed multimillion dollar annual budgets for both the Lipitor and Atherosclerosis Development programs.

Clinical Director/Lipitor Medical Team

2000-2003

As a member of the Lipitor Medical Team, directly oversaw key clinical trials and medical-marketing strategy activities as well as contributed to the overall medical and marketing strategies for the brand.

- Directly managed a number of phase IIIb/IV trials such as MIRACL, REVERSAL, BELLES and SPARCL including management of clinical study teams and budgets
- Led medical-marketing initiative to handle emerging scientific issues and competitive threats including new market entrants, HDL-C and novel pleiotropic effects of statins.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.